Navigation Links
Striking a Gold Mine: H5N1 Vaccine may Serve as an Antidote for Mutants and Variants

As a breather and news that spells heaven for millions of avian influenza patients there is a research by scientists at St. Jude Children’s Research Hospital //. According to them they have developed in the lab a vaccine that is potent against one antigenic variant of the avian influenza virus H5N1. The scientific discovery is that this vaccine also has the ability to protect humans against future variants/mutants of the virus.

The great thing about such vaccines is that these can be used as stockpiles of medicine and used as and when required. This would save time and many lives unless new vaccines can be found against those variants.

A prepublication report on the study appears in the online issue of Journal of Infectious Diseases (JID).

The researchers showed that the vaccine completely protected ferrets from a lethal nasal infection against not only the original virus the vaccine was made to thwart, but also against a newer variant that has already proved fatal to humans. The ferrets experienced a more significant reduction of virus multiplication than otherwise would have occurred, the researchers reported. Moreover, the infections failed to spread out of the upper respiratory tract to the lungs or brain.

“These findings are especially significant because ferrets are known to be an excellent and accurate model of influenza infection and immune response in humans,” said Elena Govorkova, Ph.D., a staff scientist in the Department of Infectious Diseases at St. Jude. “Restricting the infection to the upper respiratory tract is important since in humans the virus has been isolated from specimens taken from the cerebrospinal fluid, feces, throat and blood serum. Therefore, limiting the spread of virus in an infected human is crucial to saving that person’s life.” Govorkova is the lead author of the JID paper and led the research team conducting the study.

The team also showed that the optimal strategy for vaccinatio n of immunologically na?ve individuals will be the use of two doses, which in the ferrets triggered more antibody protection than a single dose. Immunologically na?ve individuals are those whose immune systems have not been stimulated to respond to a particular antigen.

The St. Jude study was the first one to show cross-reactive immunity against current H5N1 variants in ferrets, according to Robert Webster, Ph.D., a member of the Infectious Diseases department and holder of the Rose Marie Thomas Chair at St. Jude. Webster is an internationally renowned expert on avian influenza viruses and is senior author of the report in JID.

Cross-reactive immunity is the protection that a virus vaccine confers against not only the same virus, but also against variants of the original virus. “Such cross-protection would allow the use of a stockpiled vaccine until a vaccine against the specific variant causing the outbreak is developed,” Webster said. “So our success with ferrets is extremely promising news.”

Using reverse genetics, the team mixed genes from a safe, laboratory bird flu virus with a gene for the hemagglutinin (HA) protein from the H5N1 virus isolated in Hong Kong. The virus uses the HA proteins on its surface to infect cells in the respiratory tract. The resulting vaccine had the outside appearance of a dangerous virus that would stimulate the immune system, but the inside genes of a harmless variety of virus that could not cause disease. The St. Jude team was the first to use reverse genetics to make a vaccine against H5N1 that moved out of the laboratory and into clinical trials.

(Source: Nwswise)
'"/>




Related medicine news :

1. Signature Campaign: Striking doctors take to the streets
2. Striking Doctors Urged By AP High Court To End Strike
3. Striking Doctors Form Human Chain, Block Traffic
4. Striking Students Asked to Vacate Hostels
5. President Kalam Meets Striking Medicos However Stir to Continue
6. Supreme Court Verdict Gives Hope to Striking Medicos
7. President Kalam Meets Striking Medicos However Stir to Continue
8. Supreme Court Verdict Gives Hope to Striking Medicos
9. Ramadoss Examines Patients At AIIMS, Warns Striking Doctors
10. Supreme Court Orders Striking Medicos To Call Off Agitation Immediate
11. No Punitive Action Against Striking Medicos if Strike Called Off
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... , ... "I have gout, and I wanted to treat it naturally," said ... to relieve gout and pain caused by varicose veins. I drank it every morning ... relieved what VA doctors called the worst sinusitis case they'd seen and relieved gas, ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical Center ... NY, on December 3rd, to benefit Holy Name Medical Center's programs and services. ... raised over $1 million - the largest event in the Center's history, both ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric ... patient safety. Only a few hospitals and facilities have earned this distinction. This ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the ... and Eric Hoessel to vice president of sales. , Litsinger joined Mirixa ...
(Date:12/8/2016)... ... 08, 2016 , ... SunView Software aims to redefine IT ... both engaging and easy to use. Coming off the heels of a successful ... its plans to roll out new AI-powered self-service enhancements to help organizations implement ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 9, 2016 Research and Markets has ... report to their offering. ... The report forecasts the global optical transceiver market ... The report covers the present scenario and the ... calculate the market size, the report considers the revenue generated from ...
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company ... severe, rare diseases, today announced that senior management will participate in ... Conference at the InterContinental Barclay Hotel in New York ... ET. About aTyr Pharma ... aTyr Pharma is engaged in the ...
(Date:12/9/2016)... Bermuda , Dec. 9, 2016  Axovant ... leading clinical-stage biopharmaceutical company focused on the treatment ... the data from a Phase 2b trial evaluating ... care donepezil, compared with donepezil plus placebo in ... that the addition of intepirdine to treatment was ...
Breaking Medicine Technology: